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Materials and Methods 
Data processing 
We obtained GWAS meta-analysis summary statistics for 25 brain disorders and 17 
phenotypes. Wherever non-European cohorts formed a part of those meta-analyses, we 
generated non-sex-stratified European-cohorts-only version of the meta-analysis of each 
disorder together with the primary analysts for each disorder to avoid bias stemming from 
ancestry differences. Prior to heritability analysis, each dataset underwent additional 
filtering: markers were excluded for not being present among the HapMap Project Phase 
3 SNPs(84), having an allele mismatch to 1000 Genomes alleles, ambiguous strand 
information, INFO score <0.9 (where available), MAF<1%, and if considerable 
missingness in the meta-analysis was observed (where available; defined as effective per-
SNP sample size less than two thirds of the 90th percentile of total sample size). To 
remove a potential source of bias, the major histocompatibility complex region (all SNPs 
on chromosome 6 between 25 and 35 Mb) was removed from all datasets, as was the 
region surrounding the APOE locus (all SNPs on chromosome 19 between 44 and 47 
Mb) from the Alzheimer’s disease summary data. 
 
Simulations 
To evaluate the robustness of these results under various scenarios, we performed 
various simulations using data from the UK Biobank(85). Details about the UK Biobank 
project are available at http://www.ukbiobank.ac.uk. Data for the current analyses were 
obtained under an approved data request (application number #18597).  
We used data from the interim release of 152,376 samples, originally genotyped on 
the UK BiLEVE Axiom array and the UK Biobank Axiom array. We filtered individuals 
for Caucasian ancestry and recommended removals to arrive at a final dataset of 120,267 
individuals. Simulated datasets were generated to evaluate the behavior of correlation 
estimates 1) under different degrees of misclassification; 2) under different heritability 
estimates for the two traits and 3) under different liability thresholds (232 simulation 
conditions, 100 replicates per condition, for a total of 2.95 billion simulated individuals).  
In each simulation replicate, two sets of simulated quantitative phenotypes with 
heritability ranging from 5-50% and prevalence ranging from 1-10% (relevant to the 
study phenotypes) were generated by assigning 5% of total SNPs to have simulated effect 
sizes drawn from 𝑁 (0, √
ℎ2
0.05 𝑀
), where h2 is the heritability and M is the total number of 
markers in the genome, standardized for minor allele frequency (p) by √2 ∗ 𝑝 ∗ (1 − 𝑝). 
Individual phenotypes were simulated by calculating the sum of mean centered betas 
multiplied by the individual’s risk alleles with the –score option in PLINK 
v1.90b3.38(86) and adding noise term e, drawn from 𝑁(0, √1 − ℎ2), to achieve phenotypes 
which sum to 𝑁(0, ℎ2). Dichotomous phenotypes were generated by assigning top 1%, 5% 
and 10% of each heritability simulation to be cases, and misclassification scenarios by 
mixing the simulated betas with those from a second, independently simulated phenotype 
in proportions ranging between 0-100%. Association statistics were created using an 
additive test in PLINK v1.90b3.38, and LDSC was used to calculate correlation 
estimates.  
 
 
Simulation results were summarized to evaluate three specific scenarios considered 
relevant to the challenges (particularly for the psychiatric disorders, due to their 
spectrum-like behavior) in brain disorder co-morbidity:  
1. Effect of misclassification on phenotype heritability. Given that we generally 
observe slightly lower heritability estimates in this study than reported in the literature 
with previous studies (which generally have used smaller, possibly less heterogeneous 
datasets), we generated 100 replicates each of simulated phenotypes at several prevalence 
and heritability values, and with varying degrees of misclassification of cases from a 
second, independent phenotype (Fig. S9A). These results demonstrate that while large-
scale misclassification will impact the estimated heritability, very large misclassification 
proportions are required to by themselves give rise to large-scale changes in the observed 
heritability to the degree shown in Table S3. 
2. Effect of co-morbidity on genetic correlation. Given the overlapping 
epidemiology of some phenotypes and the potential to observe false positive correlations 
due to non-trivial case misclassification, we created a range of phenotypes with varying 
mixing portions of correctly diagnosed cases (λ) and incorrectly diagnosed cases (1-λ) 
from an independent second phenotype and evaluated the genetic correlation between the 
hybrid phenotype and the second phenotype. This simulates the real-world scenario 
where e.g. (1-λ) proportion of bipolar cases would in fact be misclassified cases of 
schizophrenia free of bipolar disorder (Fig. S9B). We also derived a formula (see “Effect 
of co-morbidity and phenotypic misclassification on correlation estimates” below) to 
estimate the degree of misclassification required to produce the observed correlations in 
the absence of true genetic correlation (Table S6). 
3. Effect of bidirectional comorbidity on genetic correlation. We expanded the 
simulation from the previous scenario given misclassification in both directions, i.e. 
where a proportion (1-λ) of bipolar disorder cases are misclassified schizophrenia cases 
and the same proportion of schizophrenia cases are misclassified bipolar disorder cases 
(Fig. S9C). 
 
Power calculations 
Using the same methodology as described for the simulations, we created 100 
replicated pairs of datasets, each with varying sample sizes (10,000, 20,000 and 40,000 
individuals with a 50/50 case/control split, randomly selected from the UK Biobank data; 
see section above), heritabilities (1%, 5%, 10% and 20%) and polygenicity (simulating 
0.5%-100% of markers contributing to the heritability). In the second set of similarly 
created replicates, phenotypes were additionally created to be 10%, 20%, 30%, or 40% 
correlated to their pair in the first set. LDSC was used to calculate the correlation 
between the pair (Figure S10). 
 
Heritability analysis 
For a given trait, the total additive common SNP heritability in a set of GWAS 
summary statistics (h2g) is estimated by regressing the association χ2 statistic of a SNP 
against the total amount of common genetic variation tagged by that SNP (i.e., the sum of 
r2 between that SNP and all surrounding SNPs within a 1 Mb window, termed the LD 
score). The LD scores themselves, for each SNP with MAF 5-50% in the Hapmap3 data, 
were obtained from previously published data(87) (https://github.com/bulik/ldsc) but 
 
 
edited by removing the at the time erroneously included HLA region markers [chr6, 20-
36 Mb]. Genetic correlations, rg, (i.e., the genome-wide average shared genetic risk) for a 
pair of phenotypes was similarly estimated by regressing the product of Z-score for each 
phenotype for each SNP, instead of the χ2 statistic. The LD score referenced above is 
estimated from a common reference panel (for this work, the European subset of the 1000 
Genomes Project reference). In this framework, including LD in the regression allows us 
to distinguish and account for LD-independent error sources (such as sample sharing and 
population stratification) from LD-dependent sources, like polygenic signal). It is 
essential to use an approach which is not biased by sample overlaps when analyzing 
summary statistics, given the large amount of control sharing between the GWAS meta-
analyses in the study. P-values and effect directions for each phenotype were used to 
create a set of directional χ2 statistics, which were then regressed against the SNP LD 
scores (as the χ2 statistic is dependent on the amount of variation tagged by the SNP).  
A univariate regression of these statistics against the LD statistic of each SNP was 
used to estimate the heritability for each phenotype using LDSC v1.0.0(88). When 
converting the results to liability scale, we assumed that all controls were unselected for 
all brain disorders as well as coronary artery disease and Crohn’s disease from the 
additional phenotypes (u = 1 for the formula presented in (89)). Phenotypes with a 
univariate heritability Z-score < 2 were excluded from further analysis (cardioembolic, 
large-, and small-vessel stroke and agreeableness personality measure), leaving 21 brain 
disorder phenotypes and 16 traits of interest. In the genetic correlation analysis, the 
product of χ2 statistics from the two phenotypes was similarly regressed.  
Significance was assessed by Bonferroni multiple testing correction by estimating 
the number of independent brain disorder phenotypes by matrix decomposition of the 
genetic correlation results using matSpD (see Links)(90, 91). The number of independent 
disorder phenotypes was estimated to be 17.7943 (from 22 initial disorders, after 
exclusions), yielding a Bonferroni-corrected threshold of p < 3.35 x 10-4 for disorder-
disorder pairs; 12.1925 independent phenotypes (from 16 initial phenotypes, after 
exclusions) for a threshold of p < 7.33 x 10-4 for phenotype-phenotype pairs and a total of 
216.96 disorder-phenotype pairs for a threshold of p < 2.30 x 10-4.  
 
Functional enrichment and partitioning analysis 
Partitioning analysis was conducted using LDSC v1.0.0(88), using stratified LD 
score regression to identify enriched cell type groups, expanding on the work described in 
Finucane et al(92). First, we obtained genome annotations for each of ten cell type 
groups, created by taking a union of regions with any of four histone modifications 
(H3K4me1, H3K4me3, H3K27ac, H3K9ac) in any cell type belonging to the cell type 
group. We then added each of these ten annotations to the full baseline model one at a 
time and performed LD score regression for each of the resulting ten models. For each of 
these ten analyses, we computed a Z-score for the regression coefficient corresponding to 
the cell type group, and we used this to test the hypothesis that the cell type group 
contributes positively to SNP heritability after controlling for the 53 categories in the full 
baseline model. Significance threshold was estimated from the number of independent 
phenotypes across 10 tissue categories and 53 functional categories (latter evaluated as 24 
independent categories due to overlapping category structure) for Bonferroni thresholds 
 
 
of p < 2.81 x 10-4 and 1.17 x 10-4, respectively. For the behavioral-cognitive traits and 
additional traits, the corresponding thresholds were p < 4.10 x 10-4 and p < 1.71 x 10-4.  
 
Correlation between heritability and dataset-specific factors 
A weighted-least squares analysis was conducted among the brain disorder 
phenotypes in R, version 3.2, to determine what, if any, phenotype and dataset descriptive 
factors correlate with univariate heritability estimates. Weights were estimated using the 
squares of the standard errors of the univariate heritability estimates from the LD score 
regression analysis. 
 
Supplementary text 
 
Effect of co-morbidity and phenotypic misclassification on correlation estimates 
We derived a formula to quantify the effect of case misclassification on the 
estimated genetic correlation between two traits, given the degree of misclassification, 
the observed heritability and the true genetic correlation. We assume both traits have 
similar sample and population prevalence.  
Let λ be the fraction of correctly classified cases of phenotype 1, with the remainder 
being cases of phenotype 2 misclassified as cases of phenotype 1, β1 and β2 be true 
effects for phenotypes 1 and 2 on an arbitrary SNP. Therefore, the effect of the SNP on 
the misspecified phenotype 1 is α:  
 
𝛼 ≡ 𝜆𝛽1 + (1 − 𝜆)𝛽2 
 
Before considering the impact on the estimated genetic correlation, we note that this 
change in SNP effects means the heritability of the observed (potentially misclassified) 
phenotype may differ from the heritability of the true phenotype 1. Noting that the 
observed heritability for each phenotype is proportional to the variance of their effect 
sizes, we first calculate 
 
Var(𝛼) = Var (𝜆𝛽1 + (1 − 𝜆)𝛽2) 
               = 𝜆2 Var (𝛽1)  + 2𝜆(1 − 𝜆)Cov(𝛽1, 𝛽2) + (1 − 𝜆)
2 Var(𝛽2) 
               = 𝜆2 Var (𝛽1)  + 2𝜆(1 − 𝜆)𝑟𝑔√Var(𝛽1) Var(𝛽2) + (1 − 𝜆)
2 Var(𝛽2) 
 
Then assuming standardized regression coefficients (e.g. following the LD score 
regression model), this can be written in terms of observed (obs) and true heritabilities for 
the two phenotypes and the number of genome-wide variants M as 
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2
𝑀
= 𝜆2
ℎ1
2
𝑀
+ 2𝜆 (1 − 𝜆) 𝑟𝑔√
ℎ1
2
𝑀
√
ℎ2
2
𝑀
+  (1 − 𝜆)2  
ℎ2
2
𝑀
 
ℎ1,𝑜𝑏𝑠
2 = 𝜆2ℎ1
2 + 2𝜆 (1 − 𝜆) 𝑟𝑔√ℎ1
2ℎ2
2 + (1 − 𝜆)2ℎ2
2 
 
This allows solving for  √ℎ1
2 using a quadratic equation, 
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Note that the sign of the first term in the numerator will be opposite of the sign of 𝑟𝑔. 
Therefore if we select the sign of the phenotype so that  𝑟𝑔 > 0, then we must add the 
second term to ensure √ℎ1
2 > 0. This gives us 
 
√ℎ1
2 =  
−(1 − 𝜆) 𝑟𝑔√ℎ2
2 + √(1 − 𝜆)2(𝑟𝑔
2 − 1) ℎ2
2 +  ℎ1,𝑜𝑏𝑠
2   
𝜆
 
 
Note that this will not be bounded above by one when 𝜆 is small. This is not 
surprising since a small 𝜆 implies that most of the cases reported for phenotype 1 are in 
fact cases for phenotype 2, making particular combinations of ℎ2
2,  ℎ1,𝑜𝑏𝑠
2  and 𝑟𝑔 infeasible 
for certain values of 𝜆. From the above, the determinant of the quadratic form must be 
positive, thus 
 
 ℎ1,𝑜𝑏𝑠
2 ≥ (1 − 𝜆)2(1 −  𝑟𝑔
2) ℎ2
2 
 
Similarly, the determinant of the quadratic formula, solving for ℎ2
2, implies 
 
ℎ1
2 ≤
 ℎ1,𝑜𝑏𝑠
2   
𝜆2(1 − 𝑟𝑔
2)
 
 
This is the case unless no misclassification is present (𝜆 = 0) or the phenotypes are 
functionally equivalent (𝑟𝑔
2 = 1). 
 
We can now return to the original question regarding the relationship between 𝑟𝑔 and 
𝑟𝑔,𝑜𝑏𝑠 in the presence of phenotype misclassification. We derive for the SNP effects of α 
and β2: 
 
𝑟𝑔,𝑜𝑏𝑠 ≡ Corr(𝛼, 𝛽2) 
           =  
Cov (𝛼, 𝛽2)
√Var(𝛼)Var(𝛽2)
 
           =  
Cov [𝜆𝛽1 + (1 − 𝜆)𝛽2, 𝛽2]
√Var(𝛼)Var(𝛽2)
 
 
 
           =  
𝜆 Cov (𝛽1, 𝛽2) + (1 − 𝜆) Var(𝛽2)
√Var(𝛼)Var(𝛽2)
 
           =  
𝜆 𝑟𝑔 √Var (𝛽1) Var (𝛽2) + (1 − 𝜆) Var(𝛽2)
√Var(𝛼)Var(𝛽2)
 
           = 𝜆 𝑟𝑔  
√Var(𝛽1)
√Var(𝛼)
+ (1 − 𝜆) 
√Var(𝛽2)
√Var(𝛼)
 
 
Again assuming standardized regression coefficients, the variances can be written in 
terms of heritability as 
 
𝑟𝑔,𝑜𝑏𝑠 =  
𝜆 𝑟𝑔√ℎ1
2 +  (1 − 𝜆)√ℎ2
2 
√ℎ1,𝑜𝑏𝑠
2
  
 
Rearranging and substituting the expression for √ℎ1
2 from above, assuming  𝑟𝑔 > 0, 
gives 
𝑟𝑔 =  
𝑟𝑔,𝑜𝑏𝑠√ℎ1,𝑜𝑏𝑠
2 − (1 − 𝜆)√ℎ2
2 
𝜆 √ℎ1
2
  
 
 
     =  
𝑟𝑔,𝑜𝑏𝑠√ℎ1,𝑜𝑏𝑠
2 − (1 − 𝜆)√ℎ2
2 
𝜆 
 
𝜆
−(1 − 𝜆) 𝑟𝑔√ℎ2
2  + √(1 − 𝜆)2(𝑟𝑔
2 − 1) ℎ2
2 +  ℎ1,𝑜𝑏𝑠
2
 
     =
𝑟𝑔,𝑜𝑏𝑠√ℎ1,𝑜𝑏𝑠
2 − (1 − 𝜆)√ℎ2
2 
√(1 − 𝜆)2(𝑟𝑔
2 − 1) ℎ2
2 +  ℎ1,𝑜𝑏𝑠
2 − (1 − 𝜆) 𝑟𝑔√ℎ2
2 
  
 
Note that in the case with no misclassification, i.e. 𝜆 = 1,  
  
𝑟𝑔 =
𝑟𝑔,𝑜𝑏𝑠√ℎ1,𝑜𝑏𝑠
2
√ ℎ1,𝑜𝑏𝑠
2  
= 𝑟𝑔,𝑜𝑏𝑠 
 
To examine the effects of co-morbidity has on the estimates, Table S5 shows 
numerical solutions for the estimated true correlation of some selected disorder pairs 
based on literature estimates of co-morbidity, assuming unidirectional misclassification 
and that  ℎ1,𝑜𝑏𝑠
2  is equal to true ℎ1
2 (ie. that both disorders are roughly as heritable). For this 
table, we substituted the lambda values (see table for reference) and used the formula 
above to estimate what the true 𝑟𝑔 would be, based on the observed 𝑟𝑔 in this study. Figure 
S8 shows how the true genetic correlation estimates for those pairs behave across a range 
of λ values, given the observed 𝑟𝑔 in this study, under the same assumptions as Table S5. 
 
 
 
We further estimate what degree of unidirectional misclassification would be 
required to produce the significant rg values we observe in the paper, in the absence of 
any true correlation. Given 𝑟𝑔 = 0, 
 
𝑟𝑔,𝑜𝑏𝑠 =
(1 − 𝜆)√ℎ2
2
 ℎ1,𝑜𝑏𝑠
2  
 
𝜆 =  1 −  𝑟𝑔,𝑜𝑏𝑠
 ℎ1,𝑜𝑏𝑠
2
√ℎ2
2
 
 
Table S6 lists the implied values of misclassification (1-𝜆) required to produce the 
observed significant 𝑟𝑔 values between brain disorders in the study, if no true correlation 
between the phenotypes exists.  
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Fig. S1A. Heritability estimates for brain disorders 
Red bars denote psychiatric disorders, while blue bars denote neurological disorders. 
ADHD – attention deficit hyperactivity disorder; ASD – autism spectrum disorder; ICH – 
intracerebral hemorrhage; MDD – major depressive disorder; OCD – obsessive-
compulsive disorder; PTSD – post-traumatic stress disorder. Error bars show one 
standard error. 
  
 
 
 
 
 
Fig. S1B. Heritability estimates for quantitative and additional phenotypes 
BMI – body-mass index. Heritabilities are reported on the observed scale for quantitative 
phenotypes (q) and liability scale for dichotomous phenotypes (d). Error bars show one 
standard error. 
  
 
 
 
 
Fig. S1C. Heritability and effective sample size 
ADHD – attention deficit hyperactivity disorder; ASD – autism spectrum disorder; ICH – 
intracerebral hemorrhage; MDD – major depressive disorder; OCD – obsessive-
compulsive disorder; PTSD – post-traumatic stress disorder. Shaded area shows 95% 
confidence interval. Error bars show one standard error. 
  
 
 
 
 
Fig. S1D. Heritability and case/control ratio 
ADHD – attention deficit hyperactivity disorder; ASD – autism spectrum disorder; ICH – 
intracerebral hemorrhage; MDD – major depressive disorder; OCD – obsessive-
compulsive disorder; PTSD – post-traumatic stress disorder. Shaded area shows 95% 
confidence interval. Error bars show one standard error. 
  
 
 
 
 
Fig. S1E. Heritability and disorder prevalence 
ADHD – attention deficit hyperactivity disorder; ASD – autism spectrum disorder; ICH – 
intracerebral hemorrhage; MDD – major depressive disorder; OCD – obsessive-
compulsive disorder; PTSD – post-traumatic stress disorder. Shaded area shows 95% 
confidence interval. Error bars show one standard error. 
 
  
 
 
 
 
Fig. S1F. Heritability and average age of onset for the disorder. 
ADHD – attention deficit hyperactivity disorder; ASD – autism spectrum disorder; ICH – 
intracerebral hemorrhage; MDD – major depressive disorder; OCD – obsessive-
compulsive disorder; PTSD – post-traumatic stress disorder. Shaded area shows 95% 
confidence interval. Error bars show one standard error. 
 
  
 
 
Fig. S2A. Genetic correlations against power to detect heritability 
 
 
 
Red points show significant correlations among all disorder-disorder pairs. Two outlier 
values over 1 (see Table S7A) have been reduced to 1. The points close or equal to rg = 1 
are pairs of a top-level disorder with a subtype of the same disorder, where high 
correlation is expected, ie. all migraine and migraine with aura. 
 
  
 
 
Fig. S2B. Inverses of standard errors against power to detect heritability  
 
 
 
Red points show significant correlations among all disorder-disorder pairs. SE – standard 
error. 
  
 
 
Fig. S2C. Matrix of standard errors for the genetic correlations for disorder-
disorder pairs. 
 
 
Plotted values indicate 1/standard error * 1/25 (1/25 chosen for scaling convenience); 
darker shades indicate tests with more power. Six outlier values over 1 (see Table S7A) 
have been reduced to 1. Asterisks highlight results which are significant after Bonferroni 
correction. ADHD - attention deficit hyperactivity disorder; OCD – obsessive-
compulsive disorder; PTSD – post-traumatic stress disorder.  
 
  
 
 
Fig. S2D. Matrix of standard errors for the genetic correlations for disorder-
phenotype pairs. 
 
Plotted values indicate 1/standard error * 1/25 (1/25 chosen for scaling convenience); 
darker shades indicate tests with more power. 39 outlier values over 1 (see Table S7B) 
have been reduced to 1. Asterisks highlight results which are significant after Bonferroni 
correction. ADHD - attention deficit hyperactivity disorder; ASD – autism spectrum 
disorder; BMI – body-mass index; ICH – intracerebral hemorrhage; MDD – major 
depressive disorder; OCD – obsessive-compulsive disorder; PTSD – post-traumatic stress 
disorder.  
 
 
  
 
 
 
 
 
Fig. S3A and B. Genetic correlations for attention-deficit hyperactivity disorder 
(top) and anorexia nervosa (bottom).  
ADHD - attention deficit hyperactivity disorder; ASD – autism spectrum disorder; ICH – 
intracerebral hemorrhage; MDD – major depressive disorder; OCD – obsessive-
compulsive disorder; PTSD – post-traumatic stress disorder. P-values for correlation are 
shown at the end of each bar. Error bars show one standard error. 
  
 
 
 
 
 
Fig. S3C and D. Genetic correlations for anxiety disorders (top) and autism 
spectrum disorder (bottom).  
ADHD - attention deficit hyperactivity disorder; ASD – autism spectrum disorder; ICH – 
intracerebral hemorrhage; MDD – major depressive disorder; OCD – obsessive-
compulsive disorder; PTSD – post-traumatic stress disorder. P-values for correlation are 
shown at the end of each bar. Error bars show one standard error. 
  
 
 
 
 
Fig. S3E and F. Genetic correlations for bipolar disorder (top) and major depressive 
disorder (bottom).  
ADHD - attention deficit hyperactivity disorder; ASD – autism spectrum disorder; ICH – 
intracerebral hemorrhage; MDD – major depressive disorder; OCD – obsessive-
compulsive disorder; PTSD – post-traumatic stress disorder. P-values for correlation are 
shown at the end of each bar. Error bars show one standard error.  
 
 
 
 
 
 
Fig. S3G and H. Genetic correlations for obsessive-compulsive disorder (top) and 
post-traumatic stress disorder (bottom).  
ADHD - attention deficit hyperactivity disorder; ASD – autism spectrum disorder; ICH – 
intracerebral hemorrhage; MDD – major depressive disorder; OCD – obsessive-
compulsive disorder; PTSD – post-traumatic stress disorder. P-values for correlation are 
shown at the end of each bar. Error bars show one standard error. 
 
 
 
 
 
Fig. S3I and J. Genetic correlations for schizophrenia (top) and Tourette Syndrome 
(bottom).  
ADHD - attention deficit hyperactivity disorder; ASD – autism spectrum disorder; ICH – 
intracerebral hemorrhage; MDD – major depressive disorder; OCD – obsessive-
compulsive disorder; PTSD – post-traumatic stress disorder. P-values for correlation are 
shown at the end of each bar. Error bars show one standard error. 
  
 
 
 
 
Fig. S4A and B. Genetic correlations for Alzheimer’s disease (top) and epilepsy 
(bottom).  
ADHD - attention deficit hyperactivity disorder; ASD – autism spectrum disorder; ICH – 
intracerebral hemorrhage; MDD – major depressive disorder; OCD – obsessive-
compulsive disorder; PTSD – post-traumatic stress disorder. P-values for correlation are 
shown at the end of each bar. Error bars show one standard error. 
  
 
 
 
 
Fig. S4C and D. Genetic correlations for focal epilepsy (top) and generalized 
epilepsy (bottom).  
ADHD - attention deficit hyperactivity disorder; ASD – autism spectrum disorder; ICH – 
intracerebral hemorrhage; MDD – major depressive disorder; OCD – obsessive-
compulsive disorder; PTSD – post-traumatic stress disorder. P-values for correlation are 
shown at the end of each bar. Error bars show one standard error. 
  
 
 
 
 
 
Fig. S4E and F. Genetic correlations for intracerebral hemorrhage (top) and 
ischemic stroke (bottom).  
ADHD - attention deficit hyperactivity disorder; ASD – autism spectrum disorder; ICH – 
intracerebral hemorrhage; MDD – major depressive disorder; OCD – obsessive-
compulsive disorder; PTSD – post-traumatic stress disorder. P-values for correlation are 
shown at the end of each bar. Error bars show one standard error. 
  
 
 
 
 
 
 
Fig. S4G and H. Genetic correlations for early-onset stroke (top) and migraine 
(bottom).  
ADHD - attention deficit hyperactivity disorder; ASD – autism spectrum disorder; ICH – 
intracerebral hemorrhage; MDD – major depressive disorder; OCD – obsessive-
compulsive disorder; PTSD – post-traumatic stress disorder. P-values for correlation are 
shown at the end of each bar. Error bars show one standard error.  
 
 
 
 
 
 
Fig. S4I and J. Genetic correlations for migraine without aura (top) and migraine 
with aura (bottom). 
ADHD - attention deficit hyperactivity disorder; ASD – autism spectrum disorder; ICH – 
intracerebral hemorrhage; MDD – major depressive disorder; OCD – obsessive-
compulsive disorder; PTSD – post-traumatic stress disorder. P-values for correlation are 
shown at the end of each bar. Error bars show one standard error.  
 
 
 
 
Fig. S4K and L. Genetic correlations for multiple sclerosis (top) and Parkinson’s 
disease (bottom).  
ADHD - attention deficit hyperactivity disorder; ASD – autism spectrum disorder; ICH – 
intracerebral hemorrhage; MDD – major depressive disorder; OCD – obsessive-
compulsive disorder; PTSD – post-traumatic stress disorder. P-values for correlation are 
shown at the end of each bar. Error bars show one standard error. 
 
 
 
 
 
 
Fig. S5A and B. Genetic correlations for psychiatric and neurological disorders 
against cognitive measures. 
Asterisks highlight results which are significant after Bonferroni correction. ADHD - 
attention deficit hyperactivity disorder; ASD – autism spectrum disorder; MDD – major 
depressive disorder; OCD – obsessive-compulsive disorder; PTSD – post-traumatic stress 
disorder; ICH – intracerebral hemorrhage. Dotted line divides the psychiatric phenotypes 
from the neurological phenotypes. Error bars show one standard error. 
  
 
 
 
Fig. S6A. Genetic correlations for psychiatric disorders and four personality axes. 
Grey sectors denote the extent of genetic correlation between each brain disorder and the 
four personality axes. Red line denotes zero correlation, with positive correlations on the 
outside and negative correlations on the inside. Error bars show one standard error. 
Asterisks highlight results which are significant after Bonferroni correction. Consc. – 
Conscientiousness; ADHD - attention deficit hyperactivity disorder; ASD – autism 
spectrum disorder; MDD – major depressive disorder; OCD – obsessive-compulsive 
disorder; PTSD – post-traumatic stress disorder. 
 
 
  
 
 
 
Fig. S6B. Genetic correlations for neurological disorders and four personality axes. 
Grey bars denote the extent of genetic correlation between each brain disorder and the 
four personality axes. Red line denotes zero correlation, with positive correlations on the 
outside and negative correlations on the inside. Error bars show one standard error. 
Asterisks highlight results which are significant after Bonferroni correction. Consc. – 
Conscientiousness; ICH – intracerebral hemorrhage. 
  
 
 
 
 
Fig. S7A. Tissue category heritability enrichment analysis in psychiatric phenotypes 
ADHD – attention deficit hyperactivity disorder; CNS – central nervous system; GI – 
gastro-intestinal system; OCD – obsessive-compulsive disorder; PTSD – post-traumatic 
stress disorder. Results for largely overlapping dataset in schizophrenia has been 
previously reported in Finucane et al(92). Black line denotes significance threshold for 
Bonferroni multiple testing correction, p=2.81 x 10-4. Only positive enrichment reported. 
  
 
 
 
Fig. S7B. Tissue category heritability enrichment analysis in neurological 
phenotypes 
CNS – central nervous system; GI – gastro-intestinal system. Black line denotes 
significance threshold for Bonferroni multiple testing correction, p=2.81 x 10-4. Only 
positive enrichment reported. 
  
 
 
 
Fig. S7C. Tissue category heritability enrichment analysis in quantitative and 
additional phenotypes 
BMI – body-mass index. CNS – central nervous system; GI – gastro-intestinal system. 
Results for identical datasets in BMI, Crohn’s disease and height have been previously 
reported in Finucane et al(92), and those for depressive symptoms in Okbay et al(93). 
The black line denotes significance threshold for Bonferroni multiple testing correction, 
p=4.10 x 10-4. Only positive enrichment reported.  
 
 
 
Fig. S7D. Partitioned heritability analysis across 53 functional categories in study 
disorders  
ADHD - attention deficit hyperactivity disorder; ICH – intracerebral hemorrhage; MDD 
– major depressive disorder; OCD – obsessive-compulsive disorder; PTSD – post-
traumatic stress disorder. Results for a largely overlapping dataset in schizophrenia have 
been previously reported in Finucane et al(92). The black line denotes significance 
threshold for Bonferroni multiple testing correction, p=1.17 x 10-4. Only positive 
enrichment reported. 
 
  
 
 
 
 
 
 
Fig. S8. Effect of case misclassification on true underlying genetic correlation given 
the observed results. 
ADHD - attention deficit hyperactivity disorder; BIP – bipolar disorder; OCD – 
obsessive-compulsive disorder; SCZ – schizophrenia. Genetic correlations as a function 
of misclassification based on derivation described in the section “Effect of co-morbidity 
and phenotypic misclassification on correlation estimates”, for the same phenotype pairs 
as reported in Table S5. 
  
 
 
 
 
Fig. S9A. Effect of case misclassification on observed heritability 
See Supplementary Text “Effect of co-morbidity and phenotypic misclassification on 
correlation estimates” for details. Error bars show one standard error. 
  
 
 
 
 
Fig. S9B. Effect of case misclassification on genetic correlation. 
See Supplementary Text “Effect of co-morbidity and phenotypic misclassification on 
correlation estimates” for details. Error bars show one standard error. 
  
 
 
 
 
Fig. S9C. Effect of bidirectional case misclassification on genetic correlation 
See Supplementary Text “Effect of co-morbidity and phenotypic misclassification on 
correlation estimates” for details. Error bars show one standard error. 
 
  
 
 
 
 
Fig. S10. Power analysis for detecting genetic correlations. 
Shown at each combination of parameters is the fraction of simulations out of 100 
replicates which detect the simulated correlation between the pair of phenotypes and are 
within the 95% confidence interval from the true correlation.  
 
  
 
 
Table S1. Dataset features for the brain disorder phenotypes. 
ADHD – attention deficit hyperactivity disorder; OCD – obsessive-compulsive disorder; 
PTSD – post-traumatic stress disorder; Pop. prev. – population prevalence; AOE – 
average age of onset; GC – genomic control; Publ. – publication for genotype data; MUP 
– manuscript under preparation; Preval. ref. – publication for prevalence estimate; PC – 
personal communication. All age of onset estimates based on personal communication 
and constitute rough estimates. Anxiety disorders refers to a meta-analysis of five 
subtypes (generalized anxiety disorder, panic disorder, social phobia, agoraphobia and 
specific phobias; see reference). Numbers in gray denote a dataset which is non-unique, 
e.g. all cardioembolic stroke cases and controls are also part of ischemic stroke cases and 
controls, respectively. For genomic control, - : no GC; + : study-level GC; ++ : meta-
analysis GC. Note: genomic control will impact the univariate estimate of heritability, but 
the genetic correlation estimation is robust to genomic control. References are: a(94), 
b(95), c(96), d(97), e(98), f(99), g(100), h(101), i(102), j(103), k(104), l(105), m(106), 
n(107), o(108), p(109), q(110), r(111), s(112), approximated from t(113), approximated 
from u(114), v(115), w(116), and x(117). 
 
  
  
Phenotype Cases Controls Pop. prev. AOE Heritability (SE) GC Mean χ
2
Lambda Intercept (SE) Publ. Preval. ref.
Psychiatric disorders
ADHD 12,645 84,435 0.050 12 0.100 (0.011) - 1.102 1.107 1.014 (0.007) MUP m
Anorexia nervosa 3,495 11,105 0.006 15 0.172 (0.027) + 1.077 1.086 1.012 (0.008) a n
Anxiety disorders 5,761 11,765 0.100 11 0.112 (0.045) - 1.035 1.030 1.003 (0.008) b o
Autism spectrum disorder 6,197 7,377 0.010 2 0.189 (0.025) - 1.081 1.071 0.987 (0.009) c m
Bipolar disorder 20,352 31,358 0.010 25 0.205 (0.010) - 1.324 1.387 1.021 (0.010) MUP m
Major depressive disorder 16,823 25,632 0.150 32 0.112 (0.006) - 1.263 1.293 1.005 (0.010) MUP m
OCD 2,936 7,279 0.016 16 0.255 (0.037) - 1.059 1.065 1.000 (0.007) MUP p
PTSD 2,424 7,113 0.080 23 0.148 (0.065) - 1.107 1.102 1.014 (0.007) d q
Schizophrenia 33,640 43,456 0.010 21 0.256 (0.010) - 1.588 1.768 1.059 (0.012) e m
Tourette's syndrome 4,220 8,994 0.005 7 0.196 (0.025) - 1.096 1.103 1.010 (0.007) MUP r
Neurological disorders
Alzheimer's disease 17,008 37,154 0.170 65 0.130 (0.023) - 1.093 1.104 1.038 (0.007) f PC
Epilepsy 7,779 20,439 0.030 25 0.101 (0.022) + 1.047 1.057 0.993 (0.010) g s
   Focal epilepsy 4,601 17,985 0.020 15 0.053 (0.026) + 1.023 1.013 0.988 (0.009) g PC
   Generalized epilepsy 2,525 16,244 0.008 15 0.351 (0.039) + 1.065 1.081 0.960 (0.009) g PC
Intracerebral hemorrhage 1,545 1,481 0.002 70 0.156 (0.060) - 1.038 1.037 1.012 (0.007) h t
Ischemic stroke 10,307 19,326 0.010 71 0.038 (0.010) - 1.065 1.066 1.032 (0.006) i u
  Cardioembolic stroke 1,859 17,708 - - - - 1.061 1.047 1.049 (0.006) i -
  Early-onset stroke 3,274 11,012 0.003 50 0.051 (0.020) - 1.029 1.033 1.009 (0.007) i PC
  Large-vessel disease 1,817 17,708 - - - - 1.061 1.053 1.052 (0.006) i -
  Small-vessel disease 1,349 17,708 - - - - 1.048 1.047 1.052 (0.006) i -
Migraine 59,673 316,078 0.160 30 0.150 (0.007) - 1.293 1.375 1.036 (0.010) j v
  Migraine with aura 6,332 142,817 0.075 30 0.124 (0.024) - 1.077 1.087 1.003 (0.007) j w
  Migraine without aura 8,348 136,758 0.130 30 0.208 (0.025) - 1.080 1.085 1.033 (0.007) j w
Multiple sclerosis 5,545 12,153 0.002 30 0.141 (0.016) ++ 1.050 1.078 0.975 (0.008) k x
Parkinson's disease 5,333 12,019 0.002 60 0.105 (0.017) + 1.026 1.044 0.965 (0.008) l x
 
 
Table S2. Dataset features for the behavioral-cognitive and additional phenotypes 
Numbers in gray denote a sample set which is non-unique, e.g. all samples in the BMI 
analysis are also part of the height analysis. SE – standard error; Ref. – reference; ISCE - 
International Standard Classification of Education (1997); NEO-FFI - Neuroticism-
Extraversion-Openness Five-Factor Inventory; BMI – body-mass index; CAD – coronary 
artery disease; MI – myocardial infarction; (d) – dichotomous phenotype; (q) – 
quantitative phenotype. References are: a(118), b(119), c(120), d(121), e(93), f(122), 
g(123), h(124), i(125), j(126). k(127) and l(128). 
 
 
 
  
Phenotype n Heritability (SE) Mean χ
2
Lambda Intercept (SE) Ref. Definition
Cognitive measures
   Years of education (q) 293,723 0.302 (0.010) 1.645 1.475 0.938 (0.009) a Years of schooling, measured with the ISCE scale
   College attainment (d) 120,917 0.109 (0.008) 1.223 1.194 1.021 (0.009) b College completion (ISCE scale value >=5)
   Cognitive performance (q) 17,989 0.191 (0.031) 1.075 1.065 1.001 (0.009) c General cognitive ability in childhood (ages 6-18)
   Intelligence (q) 78,308 0.194 (0.010) 1.299 1.260 1.015 (0.008) d Intelligence measures (fluid intelligence scores in 
adults or general cognitive ability in children)
Personality measures
   Subjective well-being (q) 298,420 0.062 (0.005) 1.152 1.130 1.001 (0.007) e Self-assessed psychological well-being, based on 
positive affect or life satisfaction questionnaires
   Depressive symptoms (q) 161,460 0.063 (0.005) 1.153 1.133 1.000 (0.007) e Score for depressive symptoms, based on positive 
affect or life satisfaction questionnaires
   Neuroticism (q) 170,911 0.125 (0.010) 1.307 1.237 0.994 (0.010) e Personality score for neuroticism symptoms, based on 
positive affect or life satisfaction questionnaires
   Extraversion (q) 63,030 0.049 (0.008) 1.073 1.065 1.008 (0.007) f Extraversion personality trait, as measured by several 
different questionnaires
   Agreeableness (q) 17,375 - 1.010 0.999 1.001 (0.010) g NEO-FFI questionnaire for personality scores
   Conscientiousness (q) 17,375 0.070 (0.033) 1.029 1.020 1.001 (0.009) g NEO-FFI questionnaire for personality scores
   Openness (q) 17,375 0.125 (0.030) 1.037 1.041 0.988 (0.009) g NEO-FFI questionnaire for personality scores
Smoking-related measures
   Never/ever smoked (d) 74,035 0.120 (0.010) 1.103 1.090 0.996 (0.006) h Lifetime cigarette consumption >= 100
   Cigarettes per day (q) 38,617 0.057 (0.013) 1.049 1.053 1.007 (0.006) h Average or maximum number of cigarettes per day
Additional phenotypes
   BMI (q) 339,224 0.109 (0.003) 1.158 1.038 0.672 (0.008) i BMI, as measured
   Height (q) 253,288 0.312 (0.014) 2.949 2.001 1.325 (0.019) j Height, as measured
   Coronary artery disease (d) 86,995 0.098 (0.013) 1.145 1.105 1.027 (0.009) k Presence of CAD, MI, or both
   Crohn's disease (d) 20,883 0.177 (0.021) 1.242 1.143 1.028 (0.012) l Presence of Crohn’s disease
 
 
Table S3. Comparison of heritability estimates in this study with previously 
reported estimates based on SNP data. 
ADHD – attention deficit hyperactivity disorder; ESS – effective sample size; OCD – 
obsessive-compulsive disorder; SE – standard error. References previous reports are: 
a(106), b(95), c(129), d(97), e(130), f(131), g(132), h(133), and i(134). * - Previously 
reported heritability for anxiety disorders is an LDSC analysis of the same dataset; 
difference between the estimates is due to the current study estimating heritability under 
unscreened controls. 
 
 
 
 
  
Previously reported Current study
Phenotype Heritability (SE) ESS Heritability (SE) ESS Reference
Psychiatric disorders
ADHD 0.28 (0.023) 12,374 0.100 (0.011) 43,992 a
Anorexia nervosa - - 0.172 (0.027) 10,633 -
Anxiety disorders* 0.10 (0.037) 15,469 0.112 (0.045) 15,469 b
Autism spectrum disorder 0.17 (0.025) 6,729 0.189 (0.025) 10,610 a
Bipolar disorder 0.25 (0.012) 15,391 0.205 (0.010) 49,367 a
Major depressive disorder 0.21 (0.021) 18,416 0.112 (0.006) 40,627 a
OCD 0.37 (0.070) 3,394 0.255 (0.037) 8,369 c
PTSD* 0.15(0.060) 7,232 0.148 (0.065) 7,232 d
Schizophrenia 0.23 (0.008) 20,811 0.256 (0.010) 75,846 a
Tourette's syndrome 0.58 (0.090) 2,146 0.196 (0.025) 11,489 c
Neurological disorders 0.130 (0.023)
Alzheimer's disease 0.24 (0.030) 7,095 0.101 (0.022) 46,669 e
Epilepsy 0.32 (0.046) 4,041 0.053 (0.026) 22,538 f
   Focal epilepsy 0.23 (0.102) 3,229 0.351 (0.039) 14,655 f
   Generalized epilepsy 0.36 (0.117) 1,134 0.156 (0.060) 8,741 f
Intracerebral hemorrhage 0.29 (0.110) 1,663 0.038 (0.010) 3,025 g
Ischemic stroke 0.38 (0.052) 8,025 - 26,888 h
  Cardioembolic stroke 0.33 (0.074) 2,592 0.051 (0.020) 6,730 h
  Early-onset stroke - - - 10,095 h
  Large-vessel disease 0.40 (0.076) 2,698 - 6,592 -
  Small-vessel disease 0.16 (0.077) 1,993 0.150 (0.007) 5,014 h
Migraine - - 0.124 (0.024) 200,785 -
  Migraine with aura - - 0.208 (0.025) 24,253 -
  Migraine without aura - - 0.141 (0.016) 31,471 -
Multiple sclerosis 0.30 (0.030) 3,523 0.105 (0.017) 15,231 e
Parkinson's disease 0.27 (0.053) 20,798 0.105 (0.017) 14,776 i
 
 
Table S4. Heritability estimates and selected study variables in weighted-least 
squares analysis. 
P-values are uncorrected for multiple testing. Age of onset refers to the average age of 
onset of the disorder. Asterisk indicates results which are significant after Bonferroni 
correction for four tests. 
  
 
Table S5. Implied true correlations between selected phenotypes, given co-morbidity 
estimates from literature. 
ADHD – attention deficit hyperactivity disorder; OCD – obsessive-compulsive disorder. 
References used for λ values (proportion of cases correctly called cases) are a(135), 
b(136), c(137). From reference a, λ was calculated by summing over all relevant disorder 
progression paths. See Supplementary text (“Effect of co-morbidity and phenotypic 
misclassification on correlation estimates”) for further details. 
 
 
 
  
Study feature F-statistic Adjusted R
2
P-value
Case/control ratio 0.534 -0.023 0.474
Effective sample size 1.039 0.002 0.320
Phenotype prevalence 0.341 -0.032 0.566
Age of onset 10.280 0.307 0.004*
Phenotype 1 Phenotype 2 True rg Observed rg λ h1,obs h2 Reference
Schizophrenia Bipolar disorder 0.654 0.681 0.946 0.506 0.453 a
Schizophrenia OCD 0.120 0.428 0.683 0.506 0.505 b
Bipolar disorder ADHD 0.043 0.261 0.686 0.453 0.316 c
Bipolar disorder Schizophrenia 0.514 0.681 0.808 0.453 0.506 a
 
 
Table S6. Proportions of unidirectional misclassification. 
Listed are the proportions of unidirectional misclassification which would be required to 
reach the observed genetic correlation under the assumption of no true genetic correlation 
for the significantly correlated disorder-disorder pairs in this study, in order of decreasing 
significance. ADHD – attention deficit hyperactivity disorder; ASD – autism spectrum 
disorder; MDD – major depressive disorder; OCD – obsessive-compulsive disorder. 
Type-subtype pairs (e.g. epilepsy and focal epilepsy) have been excluded. 
 
 
 
Table S7 (separate file). Disorder-disorder (A), disorder-phenotype (B) and 
phenotype-phenotype (C) correlation results. 
 
  
Phenotype 1 Phenotype 2 Observed rg Misclassification %
Bipolar disorder Schizophrenia 0.681 54.5%
MDD Schizophrenia 0.338 14.8%
Bipolar disorder MDD 0.351 64.2%
MDD Migraine 0.323 24.8%
ADHD MDD 0.521 46.5%
OCD Schizophrenia 0.327 32.6%
ADHD Migraine 0.261 17.9%
Anxiety disorders MDD 0.794 79.4%
ADHD Schizophrenia 0.223 8.7%
OCD Tourette Syndrome 0.428 55.7%
Bipolar disorder OCD 0.311 25.0%
ADHD Bipolar disorder 0.261 12.7%
Anorexia nervosa OCD 0.517 34.9%
Migraine Tourette Syndrome 0.192 14.3%
MDD Migraine without aura 0.225 12.2%
Anorexia nervosa Schizophrenia 0.219 14.7%
MDD Migraine with aura 0.278 29.4%
MDD Tourette Syndrome 0.213 12.2%
MDD OCD 0.228 10.0%
ASD Schizophrenia 0.208 15.5%
 
 
Table S8. Tissue enrichment analysis for brain disorders. 
Results shown for phenotype-tissue pairs where P-value for enrichment coefficient p-
value below the Bonferroni threshold (p < 2.81 x 10-4; data for all pairs in Table S12A). 
CNS – central nervous system; Coeff. – coefficient; SE – standard error. Results for 
schizophrenia in a largely overlapping dataset have been previously reported in Finucane 
et al (38). 
 
Table S9. Tissue enrichment analysis for behavioral-cognitive phenotypes and 
additional traits 
Results shown for phenotype-tissue pairs where P-value for enrichment coefficient p-
value below the Bonferroni threshold (p < 4.10 x 10-4; data for all pairs in Table S12A). 
BMI – body-mass index; CNS – central nervous system; Coeff. – coefficient; SE – 
standard error. Results for the same dataset in height, BMI and Crohn’s disease have been 
previously reported in Finucane et al (38), and depressive symptoms in Okbay et al(93).
 
Table S10. Functional category enrichment analysis for brain disorders 
Results shown for phenotype-tissue pairs where P-value for enrichment coefficient p-
value below the Bonferroni threshold (p < 1.17 x 10-4; data for all pairs in Table S12B). 
ADHD – attention deficit hyperactivity disorder; Coeff. – coefficient; SE – standard 
error. Results for schizophrenia in a largely overlapping dataset have been previously 
reported in Finucane et al (38). 
  
Phenotype Tissue Enrichment SE Coeff. SE Coeff. p-value
Schizophrenia CNS 3.25 0.18 1.65E-07 1.92E-08 3.35E-18
Bipolar disorder CNS 3.81 0.32 1.43E-07 2.28E-08 1.69E-10
Major depressive disorder CNS 2.76 0.30 2.03E-08 3.58E-09 6.73E-09
Multiple sclerosis Hematopoietic 4.90 0.54 2.85E-07 5.44E-08 8.03E-08
Tourette Syndrome CNS 4.23 0.78 2.32E-07 5.29E-08 5.67E-06
Generalized epilepsy CNS 2.79 0.60 1.68E-07 4.34E-08 5.44E-05
Phenotype Tissue Enrichment SE Coeff. SE Coeff. p-value
Years of education CNS 2.87 0.19 9.51E-08 1.15E-08 5.66E-17
Intelligence CNS 3.38 0.31 8.34E-08 1.20E-08 2.26E-12
Height Connective_Bone 5.32 0.38 2.24E-07 3.55E-08 1.31E-10
BMI CNS 2.67 0.18 2.73E-08 4.46E-09 4.39E-10
Crohn's disease Hematopoietic 4.19 0.43 3.60E-07 6.66E-08 3.15E-08
Neuroticism CNS 2.47 0.29 3.83E-08 8.45E-09 2.95E-06
College attainment CNS 3.31 0.45 2.71E-08 6.52E-09 1.59E-05
Height Cardiovascular 4.23 0.38 1.28E-07 3.08E-08 1.66E-05
Height Other 3.42 0.21 8.26E-08 2.19E-08 7.84E-05
Depressive symptoms Adrenal_Pancreas 5.15 0.94 3.77E-08 1.04E-08 1.47E-04
Never/ever smoked CNS 3.45 0.73 3.06E-08 9.13E-09 4.04E-04
Phenotype Category Enrichment SE Coeff. SE Coeff. p-value
Major depressive disorder Conserved_LindbladToh 19.14 2.50 1.74E-07 2.52E-08 2.42E-12
Migraine Conserved_LindbladToh 16.88 2.08 1.09E-07 1.72E-08 1.15E-10
Schizophrenia Conserved_LindbladToh 11.03 1.55 6.73E-07 1.21E-07 1.27E-08
ADHD Conserved_LindbladToh 27.15 6.24 2.00E-07 4.61E-08 7.46E-06
Migraine without aura Conserved_LindbladToh 20.64 4.99 9.63E-08 2.61E-08 1.12E-04
Bipolar disorder Conserved_LindbladToh 9.95 1.98 3.80E-07 1.03E-07 1.17E-04
 
 
Table S11. Functional category enrichment analysis for behavioral-cognitive 
phenotypes and additional traits 
Results shown for phenotype-tissue pairs where P-value for enrichment coefficient p-
value below the Bonferroni threshold (p < 1.71 x 10-4; data for all pairs in Table S12B). 
BMI – body-mass index; Coeff. – coefficient; SE – standard error. Results for the same 
dataset in height and BMI have been previously reported in Finucane et al (38). 
 
 
Table S12 (separate file). Tissue (A) and functional category (B) enrichment analysis 
results for brain disorders, behavioral-cognitive phenotypes, and additional traits. 
Table S13 (separate file). Data sources, responsible consortia, and data availability. 
 
 
Phenotype Category Enrichment SE Coeff. SE Coeff. p-value
BMI Conserved_LindbladToh 16.68 1.69 2.76E-07 3.34E-08 7.28E-17
Years of education Conserved_LindbladToh 14.96 1.68 6.56E-07 8.80E-08 4.67E-14
Height Conserved_LindbladToh 11.07 1.59 5.15E-07 9.79E-08 7.20E-08
BMI H3K9ac_peaks_Trynka 7.00 0.97 1.18E-07 2.41E-08 4.79E-07
Neuroticism Conserved_LindbladToh 11.96 2.95 2.26E-07 5.10E-08 4.50E-06
Intelligence Conserved_LindbladToh 13.50 2.56 3.51E-07 8.24E-08 9.77E-06
College attainment Conserved_LindbladToh 16.32 3.31 1.61E-07 3.92E-08 1.98E-05
